M Diebold1, L Kappos1, T Derfuss2. 1. Neurologische Klinik und Poliklinik, Universitätsspital Basel, Petersgraben 4, 4031, Basel, Schweiz. 2. Neurologische Klinik und Poliklinik, Universitätsspital Basel, Petersgraben 4, 4031, Basel, Schweiz. Tobias.Derfuss@usb.ch.
Abstract
BACKGROUND: The treatment of autoimmune disorders of the nervous system is based on interventions for the underlying immune phenomena. OBJECTIVE: To summarize concepts of cell depletion and myeloablation studied in the context of neuroimmunological disorders. METHOD: Evaluation of the available literature on multiple sclerosis as the most widely studied neuroimmunological entity. RESULTS: Three concepts have been introduced: classical immunosuppressants, such as azathioprine, mitoxantrone and cyclophosphamide exert general lymphopenic effects and thereby moderately decrease disease activity. Myeloablative regimens combined with autologous hematopoietic stem cell transplantation have a profound and in most cases long-lasting impact on autoimmunity at the cost of potentially life-threatening side effects. Alemtuzumab (anti-CD52), rituximab and ocrelizumab (both anti-CD20) are depleting antibodies directed against certain lymphocyte subsets and substantially ameliorate disease activity in relapsing-remitting multiple sclerosis. Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis. CONCLUSIONS: Most of the presented cell-depleting and myeloablative therapies are highly effective treatment options but are also accompanied by significant risks. In the context of the increasing number of alternative immunomodulatory options the indications for use should be cautiously considered.
BACKGROUND: The treatment of autoimmune disorders of the nervous system is based on interventions for the underlying immune phenomena. OBJECTIVE: To summarize concepts of cell depletion and myeloablation studied in the context of neuroimmunological disorders. METHOD: Evaluation of the available literature on multiple sclerosis as the most widely studied neuroimmunological entity. RESULTS: Three concepts have been introduced: classical immunosuppressants, such as azathioprine, mitoxantrone and cyclophosphamide exert general lymphopenic effects and thereby moderately decrease disease activity. Myeloablative regimens combined with autologous hematopoietic stem cell transplantation have a profound and in most cases long-lasting impact on autoimmunity at the cost of potentially life-threatening side effects. Alemtuzumab (anti-CD52), rituximab and ocrelizumab (both anti-CD20) are depleting antibodies directed against certain lymphocyte subsets and substantially ameliorate disease activity in relapsing-remitting multiple sclerosis. Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis. CONCLUSIONS: Most of the presented cell-depleting and myeloablative therapies are highly effective treatment options but are also accompanied by significant risks. In the context of the increasing number of alternative immunomodulatory options the indications for use should be cautiously considered.
Authors: R Press; H Askmark; A Svenningsson; O Andersen; H W Axelson; U Strömberg; A Wahlin; C Isaksson; J E J Johansson; H Hägglund Journal: J Neurol Neurosurg Psychiatry Date: 2013-11-21 Impact factor: 10.154
Authors: O A Khan; M Zvartau-Hind; C Caon; M U Din; M Cochran; D Lisak; A C Tselis; J A Kamholz; J Y Garbern; R P Lisak Journal: Mult Scler Date: 2001-06 Impact factor: 6.312
Authors: Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston Journal: Lancet Date: 2012-11-01 Impact factor: 79.321
Authors: E Havrdova; R Zivadinov; J Krasensky; M G Dwyer; I Novakova; O Dolezal; V Ticha; L Dusek; E Houzvickova; J L Cox; N Bergsland; S Hussein; A Svobodnik; Z Seidl; M Vaneckova; D Horakova Journal: Mult Scler Date: 2009-05-22 Impact factor: 6.312
Authors: Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers Journal: Lancet Date: 2002 Dec 21-28 Impact factor: 79.321